What is Medicenna Therapeutics Corp.'s (MDNA.TO) StockRank?

MoatMap's StockRank for Medicenna Therapeutics Corp. (MDNA.TO) is 1/100, with a Strong Sell signal. This is a composite score combining Quality (27), Value (25), and Momentum (11) factor ranks across MoatMap's 20,000+ stock universe.

Does Medicenna Therapeutics Corp. have an economic moat?

Medicenna Therapeutics Corp. (MDNA.TO) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Medicenna Therapeutics Corp. a buy, hold, or sell?

MoatMap's current signal for Medicenna Therapeutics Corp. (MDNA.TO) is Strong Sell, based on a StockRank of 1/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Medicenna Therapeutics Corp. in?

Medicenna Therapeutics Corp. (MDNA.TO) operates in the Healthcare sector, specifically the Biotechnology industry (Canada).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

MDNA.TO

STRONG SELLREMOVE

Medicenna Therapeutics Corp. · Healthcare · Canada · $27M · Avg Vol: $32K/d

StockRank

P/E (TTM)

—

ROE

-109.8%

D/E

0.0x

Dividend %

—

Director Trades · 180d

+$2.1K →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

A micro-cap clinical-stage immunotherapy company. It is pre-revenue, highly speculative, and lacks the validated manufacturing scale or CDMO pricing power required to benefit from our healthcare-related themes.

COMPANY DESCRIPTION

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company developing novel, highly selective Superkines designed to treat various forms of cancer. The company's competitive moat is anchored by its proprietary Superkine platform, which engineers interleukins to selectively target cancer cells while minimizing systemic toxicity. It operates as a high-potential biotechnology innovator targeting large, underserved oncology markets.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.30	-0.11	-0.26	-0.11	—
Shares	55.6M	69.6M	69.6M	78.2M	+40.6%
Debt	0	4.9M	0	0.1M	-84.5%
Equity	14.7M	20.8M	3.7M	13.5M	-2.9%
Op CF	-16.6M	-8.9M	-11.5M	-11.6M	—
Inv CF	7.1M	0	0	-23,289	—
Fin CF	2.7M	17.5M	0	16.6M	—

PRICE (1Y)-25.9%

SMA 50SMA 200

$0.29

RSI (14)

34.8

52W High

$1.39

From 52W High

0.2%

SCORE BREAKDOWN

Quality

ROIC

-85.2%6.9

ROE

-109.8%7.3

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-37.7%6.6

Piotroski

12.3

Int. Cover

—N/A

D/E Ratio

0.02x82.1

Current Ratio

2.68x49.1

Value

P/E (TTM)

—N/A

EV/EBITDA

-1.1x25.0

P/FCF

—N/A

P/B

5.7x22.8

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

21%2.9

RS 6M

-65%15.7

SMA 50/200

0.57x2.0

EPS Rev 4W

+1.4%84.8

EPS Rev 12W

—N/A

EPS Improve

-53%8.3

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$27M

P/E (Forward)

-1.8x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MDNA.TO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
MDNA.TO	Medicenna Therapeutics Corp.(you)	$27M	1	STRONG SELL
QNTM.CN	Quantum BioPharma Ltd.	$45M	2	STRONG SELL
EDSA	Edesa Biotech, Inc.	$61M	17	STRONG SELL
ENGN	enGene Therapeutics Inc.	$114M	8	STRONG SELL
MIST	Milestone Pharmaceuticals Inc.	$161M	1	STRONG SELL
MSLE	Satellos Bioscience Inc.	$119M	10	STRONG SELL
PMN	ProMIS Neurosciences, Inc.	$97M	15	STRONG SELL
NGEN	NervGen Pharma Corp.	$244M	1	STRONG SELL
OBI.L	Ondine Biomedical Inc.	$101M	20	SELL
HELP	Cybin D/B/A Helus Pharma	$245M	6	STRONG SELL

Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 35.6%

Medicenna Therapeutics Corp. (MDNA.TO) — Stock Score Summary

Medicenna Therapeutics Corp. (MDNA.TO) has a MoatMap StockRank of 1/100 based on Quality (27/100), Value (25/100), and Momentum (11/100) factor scores. The current signal is STRONG SELL. A micro-cap clinical-stage immunotherapy company. It is pre-revenue, highly speculative, and lacks the validated manufacturing scale or CDMO pricing power required to benefit from our healthcare-related themes.

Key Financial Metrics

Price	$0.29
Market Cap	$27M
P/E (Forward)	-1.83
Price/Book	5.68
Return on Equity	-109.8%
Return on Invested Capital	-85.2%
Debt/Equity	2.17
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-8M

Medicenna Therapeutics Corp. operates in the Biotechnology industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is Medicenna Therapeutics Corp.’s (MDNA.TO) StockRank?: MoatMap’s StockRank for Medicenna Therapeutics Corp. (MDNA.TO) is 1/100, with a Strong Sell signal. It is a composite of Quality (27), Value (25), and Momentum (11) factor ranks across MoatMap’s 20,000+ stock universe.
Does Medicenna Therapeutics Corp. have an economic moat?: Medicenna Therapeutics Corp. (MDNA.TO) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Medicenna Therapeutics Corp. a buy, hold, or sell?: MoatMap’s current signal for Medicenna Therapeutics Corp. (MDNA.TO) is Strong Sell, based on a StockRank of 1/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Medicenna Therapeutics Corp. in?: Medicenna Therapeutics Corp. (MDNA.TO) operates in the Healthcare sector, specifically the Biotechnology industry (Canada).